Improving Tolerance and Compliance of New Targeted Therapies with Homeopathy: A Major Challenge in Oncology
Abstract
(ISSN 2573-4393)
OBM Integrative and Complementary Medicine is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. It covers all evidence-based scientific studies on integrative, alternative and complementary approaches to improving health and wellness.
Topics contain but are not limited to:
It publishes a variety of article types: original research, review, communication, opinion, case report, study protocol, comment, conference report, technical note, book review, etc.
There is no restriction on paper length, provided that the text is concise and comprehensive. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 11.7 days from acceptance to publication (median values for papers published in this journal in the second half of 2021, 1-2 days of FREE language polishing time is also included in this period). A first decision provided to authors of manuscripts submitted to this journal are approximately 6.8 weeks (median values) after submission.
Special Issue
Homeopathy in Oncological Integrative Care
Submission Deadline: February 28, 2022 (Open) Submit Now
Guest Editor
Jean-Lionel Bagot, MD, Specialist in oncological supportive care.
1. Coordinating doctor of the Outpatients Department for Integrative Care, Groupe Hospitalier Saint Vincent,All Saints Hospital, Strasbourg, France.
2. President of the International Homeopathic Society of Supportive Care in Oncology (SHISSO).
Research interests: homeopathy; integrative oncology; oncological supportive care.
About This Topic
Although cancer treatments have much improved in efficiency and tolerance, they still have side effects that are sometimes difficult to deal with, leading patients to turn more and more often to complementary therapies. Five years after the diagnosis of their disease, 63.5% of patients still report suffering from sequelae due to the cancer itself or its treatments. How can we avoid this? With 31% of users, homeopathy is by far the most widely used complementary medicine in integrative oncology in France and in Europe. It has the advantage of having neither drug interaction nor significant side effects while its cost is very low.
Several randomised studies have confirmed the effectiveness experienced by patients and their doctors. This add-on therapy, in helping to deal with side effects, improves not only the quality of life but also the rate of survival as was demonstrated recently Pr. Michael Frass in his latest study.
The use of homeopathy in the strict framework of supportive care has enabled us to develop this therapeutic approach for the different stages of cancer treatment making it possible to combine openly "Cancer" and "Homeopathy" and publish different articles on this topic.
As Guest Editor, I’m delighted to warmly invite authors, researchers and clinicians, to contribute to this Special Issue, covering the whole scope of the scientific and experiential investigation concerning homeopathy in integrative oncology.
Whether through the publication of clinical cases, the sharing of experience, qualitative or quantitative studies, mini reviews or even personal points of views, I invite all physicians specialising in this field, as well as pharmacists, dentists and veterinaries to take part in this Special Issue.
I sincerely hope that this sharing of knowledge will help towards making our practice better known within the scientific community and to ensure its progress for the greater good of our patients.
Keywords
homeopathy; integrative oncology; quality of life; supportive care; survival.
Publication
Improving Tolerance and Compliance of New Targeted Therapies with Homeopathy: A Major Challenge in OncologyAbstract The application of targeted therapies (TT) in oncology has prolonged survivals and even enabled complete remission of cancers previously considered incurable. With small therapeutic indices, the reduction in dosage or spacing out of the doses of TT due to side effects, represents a significant loss of treatment opportunity for the patients [...] |
TOP